Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials

Wykoff Charles C. and Abreu Francis and Adamis Anthony P. and Basu Karen and Eichenbaum David A. and Haskova Zdenka and Lin Hugh and Loewenstein Anat and Mohan Shaun and Pearce Ian A. and Sakamoto Taiji and Schlottmann Patricio G. and Papp András and Tóth-Molnár Edit and Kollaborációs szervezet: YOSEMITE and RHINE Investigators (kollab. közrem.): Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
LANCET, 399 (10326). pp. 741-755. ISSN 0140-6736 (2022)

[thumbnail of TheLancet741-755..pdf]
Preview
Text
TheLancet741-755..pdf - Published Version

Download (944kB) | Preview
Item Type: Journal Article
Szerzők száma: 393
Journal or Publication Title: LANCET
Date: 2022
Volume: 399
Number: 10326
Page Range: pp. 741-755
ISSN: 0140-6736
Faculty/Unit: Albert Szent-Györgyi Medical School
Institution: Szegedi Tudományegyetem
Language: English
MTMT rekordazonosító: 32673645
DOI azonosító: https://doi.org/10.1016/S0140-6736(22)00018-6
Date Deposited: 2022. Apr. 25. 15:04
Last Modified: 2022. Apr. 25. 15:04
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/24213
Web of Science® Times Cited: 114 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year